

Peter W M Johnson

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8285309/publications.pdf>

Version: 2024-02-01

256
papers

18,362
citations

11651

70
h-index

13771

129
g-index

265
all docs

265
docs citations

265
times ranked

19238
citing authors

#	ARTICLE	IF	CITATIONS
1	Immune responses against SARS-CoV-2 variants after two and three doses of vaccine in B-cell malignancies: UK PROSECO study. <i>Nature Cancer</i> , 2022, 3, 552-564.	13.2	51
2	Prognostic significance of crown-like structures to trastuzumab response in patients with primary invasive HER2+ breast carcinoma. <i>Scientific Reports</i> , 2022, 12, .	3.3	7
3	Smart salvage treatment for Hodgkin lymphoma. <i>Blood</i> , 2022, 139, 3563-3564.	1.4	0
4	KIR2DS2 Expression Identifies NK Cells With Enhanced Anticancer Activity. <i>Journal of Immunology</i> , 2022, 209, 379-390.	0.8	5
5	COVID-19: Third dose booster vaccine effectiveness against breakthrough coronavirus infection, hospitalisations and death in patients with cancer: A population-based study. <i>European Journal of Cancer</i> , 2022, 175, 1-10.	2.8	34
6	Prognostic indices in diffuse large B-cell lymphoma in the rituximab era: an analysis of the UK National Cancer Research Institute R-CHOP 14 versus 21 phase 3 trial. <i>British Journal of Haematology</i> , 2021, 192, 1015-1019.	2.5	8
7	Comparative analysis of gene expression platforms for cell-of-origin classification of diffuse large B-cell lymphoma shows high concordance. <i>British Journal of Haematology</i> , 2021, 192, 599-604.	2.5	7
8	The effect of clinical decision making for initiation of systemic anticancer treatments in response to the COVID-19 pandemic in England: a retrospective analysis. <i>Lancet Oncology</i> , The, 2021, 22, 66-73.	10.7	37
9	Efficacy and safety results from CheckMate 140, a phase 2 study of nivolumab for relapsed/refractory follicular lymphoma. <i>Blood</i> , 2021, 137, 637-645.	1.4	69
10	Advanced Hodgkin lymphoma in the East of England: a 10-year comparative analysis of outcomes for real-world patients treated with ABVD or escalated-BEACOPP, aged less than 60 years, compared with 5-year extended follow-up from the RATHL trial. <i>Annals of Hematology</i> , 2021, 100, 1049-1058.	1.8	7
11	KDM5 inhibition offers a novel therapeutic strategy for the treatment of <i>KMT2D</i> mutant lymphomas. <i>Blood</i> , 2021, 138, 370-381.	1.4	33
12	Epigenetics of Indolent Lymphoma and How It Drives Novel Therapeutic Approaches—Focus on EZH2-Targeted Drugs. <i>Current Oncology Reports</i> , 2021, 23, 76.	4.0	0
13	Moving the goalposts while scoring—the dilemma posed by new PET technologies. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 2696-2710.	6.4	13
14	Comparison of immunohistochemistry and gene expression profiling subtyping for diffuse large B-cell lymphoma in the phase III clinical trial of R-CHOP±Aibrutinib. <i>British Journal of Haematology</i> , 2021, 194, 83-91.	2.5	5
15	Personalized medicine for Hodgkin lymphoma: Mitigating toxicity while preserving cure. <i>Hematological Oncology</i> , 2021, 39, 39-45.	1.7	1
16	O17-1 Subcutaneous (SC) epcoritamab induces complete responses across R/R B-cell NHL subtypes: Updated dose-escalation data. <i>Annals of Oncology</i> , 2021, 32, S292.	1.2	0
17	Antibody responses after SARS-CoV-2 vaccination in patients with lymphoma. <i>Lancet Haematology</i> , the, 2021, 8, e542-e544.	4.6	64
18	Risk prediction of covid-19 related death and hospital admission in adults after covid-19 vaccination: national prospective cohort study. <i>BMJ</i> , The, 2021, 374, n2244.	6.0	208

#	ARTICLE	IF	CITATIONS
19	Efficacy and Safety of Parsaclisib in Patients with Relapsed or Refractory Marginal Zone Lymphoma: Primary Analysis from a Phase 2 Study (CITADEL-204). <i>Blood</i> , 2021, 138, 44-44.	1.4	6
20	Selinexor Enhances NK Cell Activation Against Malignant B Cells via Downregulation of HLA-E. <i>Frontiers in Oncology</i> , 2021, 11, 785635.	2.8	9
21	BCR signaling contributes to autophagy regulation in chronic lymphocytic leukemia. <i>Leukemia</i> , 2020, 34, 640-644.	7.2	12
22	Distinct genetic changes reveal evolutionary history and heterogeneous molecular grade of DLBCL with MYC/BCL2 double-hit. <i>Leukemia</i> , 2020, 34, 1329-1341.	7.2	66
23	Living risk prediction algorithm (QCOVID) for risk of hospital admission and mortality from coronavirus 19 in adults: national derivation and validation cohort study. <i>BMJ</i> , The, 2020, 371, m3731.	6.0	471
24	BET inhibitors synergize with venetoclax to induce apoptosis in MYC-driven lymphomas with high BCL-2 expression. <i>Blood Advances</i> , 2020, 4, 3316-3328.	5.2	24
25	Resources-Stratified Guidelines for Classical Hodgkin Lymphoma. <i>International Journal of Environmental Research and Public Health</i> , 2020, 17, 1783.	2.6	9
26	Progressive multifocal leukoencephalopathy (PML) following autologous peripheral blood stem cell transplantation for multiple myeloma. <i>Clinical Case Reports (discontinued)</i> , 2020, 8, 938-943.	0.5	6
27	Health-related quality-of-life results from the phase 3 OPTIMISMM study: pomalidomide, bortezomib, and low-dose dexamethasone versus bortezomib and low-dose dexamethasone in relapsed or refractory multiple myeloma. <i>Leukemia and Lymphoma</i> , 2020, 61, 1850-1859.	1.3	11
28	Molecular MRD status and outcome after transplantation in NPM1-mutated AML. <i>Blood</i> , 2020, 135, 680-688.	1.4	109
29	Maximum tumor diameter is associated with event-free survival in PET-negative patients with stage I/IIA Hodgkin lymphoma. <i>Blood Advances</i> , 2020, 4, 203-206.	5.2	15
30	Genetic heterogeneity highlighted by differential FDG-PET response in diffuse large B-cell lymphoma. <i>Haematologica</i> , 2020, 105, 318-321.	3.5	5
31	Subcutaneous Epcoritamab Induces Complete Responses with an Encouraging Safety Profile across Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma Subtypes, Including Patients with Prior CAR-T Therapy: Updated Dose Escalation Data. <i>Blood</i> , 2020, 136, 45-46.	1.4	45
32	Acalabrutinib in Combination with Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisolone (R-CHOP) As First Line Therapy for Patients with Diffuse Large B-Cell Lymphoma (DLBCL): The Accept Phase Ib/II Single Arm Study. <i>Blood</i> , 2020, 136, 38-39.	1.4	3
33	Prognostication for Advanced Stage Hodgkin Lymphoma (HL) in the Modern Era: A Project from the Hodgkin Lymphoma International Study for Individual Care (HoLISTIC) Consortium. <i>Blood</i> , 2020, 136, 16-18.	1.4	2
34	elearning for cancer immunotherapy. <i>Ecancermedscience</i> , 2020, 14, ed94.	1.1	0
35	Treatment of Advanced-Stage Hodgkin Lymphoma. <i>Hematologic Malignancies</i> , 2020, , 249-264.	0.2	0
36	Interim Cell-Free Circulating Lymphoma DNA Analysis of the Phase 2 Accept Trial. <i>Blood</i> , 2020, 136, 24-25.	1.4	0

#	ARTICLE	IF	CITATIONS
37	Phase 2 Study Evaluating the Efficacy and Safety of Parsaclisib in Patients with Relapsed or Refractory Marginal Zone Lymphoma (CITADEL-204). <i>Blood</i> , 2020, 136, 27-28.	1.4	9
38	Transmission of diffuse large B-cell lymphoma by an allogeneic stem-cell transplant. <i>Haematologica</i> , 2019, 104, e174-e177.	3.5	5
39	Phase I Study of the Novel Enhancer of Zeste Homolog 2 (EZH2) Inhibitor GSK2816126 in Patients with Advanced Hematologic and Solid Tumors. <i>Clinical Cancer Research</i> , 2019, 25, 7331-7339.	7.0	110
40	Options for first line therapy of Hodgkin lymphoma. <i>Hematological Oncology</i> , 2019, 37, 82-86.	1.7	6
41	Positron Emission Tomography Score Has Greater Prognostic Significance Than Pretreatment Risk Stratification in Early-Stage Hodgkin Lymphoma in the UK RAPID Study. <i>Journal of Clinical Oncology</i> , 2019, 37, 1732-1741.	1.6	38
42	Focal skeletal ¹⁸ F-FDG uptake indicates poor prognosis in cHL regardless of extent and first-line chemotherapy. <i>British Journal of Haematology</i> , 2019, 186, 431-439.	2.5	8
43	Gene-expression profiling of bortezomib added to standard chemoimmunotherapy for diffuse large B-cell lymphoma (REMoDL-B): an open-label, randomised, phase 3 trial. <i>Lancet Oncology</i> , The, 2019, 20, 649-662.	10.7	187
44	Nivolumab for Relapsed/Refractory Diffuse Large B-Cell Lymphoma in Patients Ineligible for or Having Failed Autologous Transplantation: A Single-Arm, Phase II Study. <i>Journal of Clinical Oncology</i> , 2019, 37, 481-489.	1.6	265
45	Molecular High-Grade B-Cell Lymphoma: Defining a Poor-Risk Group That Requires Different Approaches to Therapy. <i>Journal of Clinical Oncology</i> , 2019, 37, 202-212.	1.6	187
46	Randomized Phase III Trial of Ibrutinib and Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Non-Germinal Center B-Cell Diffuse Large B-Cell Lymphoma. <i>Journal of Clinical Oncology</i> , 2019, 37, 1285-1295.	1.6	388
47	Baseline PET features to predict prognosis in primary mediastinal B cell lymphoma: a comparative analysis of different methods for measuring baseline metabolic tumour volume. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2019, 46, 1334-1344.	6.4	14
48	Current treatment paradigms for advanced stage Hodgkin lymphoma. <i>British Journal of Haematology</i> , 2019, 184, 60-71.	2.5	6
49	Ibrutinib Therapy Releases Leukemic Surface IgM from Antigen Drive in Chronic Lymphocytic Leukemia Patients. <i>Clinical Cancer Research</i> , 2019, 25, 2503-2512.	7.0	23
50	First-in-Human, Phase 1/2 Trial to Assess the Safety and Clinical Activity of Subcutaneous GEN3013 (DuoBody [®] -CD3 ⁺ -CD20) in B-Cell Non-Hodgkin Lymphomas. <i>Blood</i> , 2019, 134, 758-758.	1.4	17
51	Phase 2 Results of the iR2 Regimen (Ibrutinib, Lenalidomide, and Rituximab) in Patients with Relapsed/Refractory (R/R) Non-Germinal Center B Cell-like (Non-GCB) Diffuse Large B-Cell Lymphoma (DLBCL). <i>Blood</i> , 2019, 134, 761-761.	1.4	9
52	Clinical Impact of Ibrutinib with R-CHOP in Untreated Non-GCB DLBCL Co-Expressing BCL2 and MYC Genes in the Phase 3 Phoenix Trial. <i>Blood</i> , 2019, 134, 354-354.	1.4	10
53	High Surface IgM Levels Associate with Shorter Response Duration and Bypass of the BTK Blockade during Ibrutinib Therapy in CLL Patients. <i>Blood</i> , 2019, 134, 1752-1752.	1.4	4
54	Longitudinal Analyses of Diagnostic-Relapse Biopsies of Diffuse Large B Cell Lymphoma Reveal a Poor Risk Subset of ABC Patients Based on the Expression of a 30 Gene Panel. <i>Blood</i> , 2019, 134, 2769-2769.	1.4	0

#	ARTICLE	IF	CITATIONS
55	Optimizing therapy in advanced-stage Hodgkin lymphoma. <i>Blood</i> , 2018, 131, 1679-1688.	1.4	22
56	CHOP versus GEM-P in previously untreated patients with peripheral T-cell lymphoma (CHEMO-T): a phase 2, multicentre, randomised, open-label trial. <i>Lancet Haematology</i> , 2018, 5, e190-e200.	4.6	50
57	Does PET Reconstruction Method Affect Deauville Scoring in Lymphoma Patients?. <i>Journal of Nuclear Medicine</i> , 2018, 59, 1167-1169.	5.0	32
58	Genomic profiling reveals spatial intra-tumor heterogeneity in follicular lymphoma. <i>Leukemia</i> , 2018, 32, 1261-1265.	7.2	87
59	Augmentation of CD134 (OX40)-dependent NK anti-tumour activity is dependent on antibody cross-linking. <i>Scientific Reports</i> , 2018, 8, 2278.	3.3	38
60	Early-stage Hodgkin lymphoma in the modern era: simulation modelling to delineate long-term patient outcomes. <i>British Journal of Haematology</i> , 2018, 182, 212-221.	2.5	17
61	All that glitters is not gold - new reconstruction methods using Deauville criteria for patient reporting. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2018, 45, 316-317.	6.4	28
62	Controversies in the Treatment of Classical Hodgkin Lymphoma. <i>HemaSphere</i> , 2018, 2, e149.	2.7	11
63	RIVA - a phase IIa study of rituximab and varlilumab in relapsed or refractory B-cell malignancies: study protocol for a randomized controlled trial. <i>Trials</i> , 2018, 19, 619.	1.6	7
64	Antibodies to Costimulatory Receptor 4-1BB Enhance Anti-tumor Immunity via T Regulatory Cell Depletion and Promotion of CD8 ⁺ T Cell Effector Function. <i>Immunity</i> , 2018, 49, 958-970.e7.	14.3	114
65	Somatic cancer genetics in the UK: real-world data from phase I of the Cancer Research UK Stratified Medicine Programme. <i>ESMO Open</i> , 2018, 3, e000408.	4.5	4
66	Determinants of ovarian function after response-adapted therapy in patients with advanced Hodgkin's lymphoma (RATHL): a secondary analysis of a randomised phase 3 trial. <i>Lancet Oncology</i> , 2018, 19, 1328-1337.	10.7	62
67	Mutation screening using formalin-fixed paraffin-embedded tissues: a stratified approach according to DNA quality. <i>Laboratory Investigation</i> , 2018, 98, 1084-1092.	3.7	11
68	Variable Responses of MYC Translocation Positive Lymphoma Cell Lines To Different Combinations of Novel Agents: Impact of BCL2 Family Protein Expression. <i>Translational Oncology</i> , 2018, 11, 1147-1154.	3.7	15
69	The iR2 Regimen (Ibrutinib, Lenalidomide, and Rituximab) Is Active with a Manageable Safety Profile in Patients with Relapsed/Refractory Non-Germinal Center-like Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2018, 132, 402-402.	1.4	2
70	A Comparison of Prognostic Indices in Diffuse Large B-Cell Lymphoma within the UK NCRI R-CHOP 14 Versus 21 Phase III Trial. <i>Blood</i> , 2018, 132, 2956-2956.	1.4	2
71	Health-Related Quality of Life Among Patients with Relapsed or Refractory Multiple Myeloma Who Received Pomalidomide, Bortezomib, and Low-Dose Dexamethasone Versus Bortezomib and Low-Dose Dexamethasone - Results from the Phase 3 Optimism Study. <i>Blood</i> , 2018, 132, 1960-1960.	1.4	1
72	A Global, Randomized, Placebo-Controlled, Phase 3 Study of Ibrutinib Plus Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (RCHOP) in Patients with Previously Untreated Non-Germinal Center B-Cell-like (GCB) Diffuse Large B-Cell Lymphoma (DLBCL). <i>Blood</i> , 2018, 132, 784-784.	1.4	16

#	ARTICLE	IF	CITATIONS
73	Updated Report on Identification of Molecular Predictors of Tazemetostat Response in an Ongoing NHL Phase 2 Study. <i>Blood</i> , 2018, 132, 4097-4097.	1.4	5
74	Abstract CT162: ACCEPT: A phase Ib/II combination of acalabrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone (R-CHOP) for patients with diffuse large B-cell lymphoma (DLBCL). , 2018, , .		0
75	Primary mediastinal large B-cell lymphoma. <i>Critical Reviews in Oncology/Hematology</i> , 2017, 113, 318-327.	4.4	77
76	Prognostic models for primary mediastinal (thymic) B-cell lymphoma derived from 18F-FDG PET/CT quantitative parameters in the International Extranodal Lymphoma Study Group (IELSG) 26 study. <i>British Journal of Haematology</i> , 2017, 178, 588-591.	2.5	20
77	Response-adapted therapy in Hodgkin lymphoma. <i>Hematological Oncology</i> , 2017, 35, 33-36.	1.7	2
78	Should Response-Adapted Therapy Now Be the Standard of Care for Advanced Hodgkin's Lymphoma?. <i>Current Treatment Options in Oncology</i> , 2017, 18, 15.	3.0	6
79	In Reply to Adams and Kwee. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 97, 870-871.	0.8	0
80	Whole-brain radiotherapy or autologous stem-cell transplantation as consolidation strategies after high-dose methotrexate-based chemoimmunotherapy in patients with primary CNS lymphoma: results of the second randomisation of the International Extranodal Lymphoma Study Group-32 phase 2 trial. <i>Lancet Haematology</i> , 2017, 4, e510-e523.	4.6	258
81	Interim Report from a Phase 2 Multicenter Study of Tazemetostat, an EZH2 Inhibitor: Clinical Activity and Favorable Safety in Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017, 17, S380-S381.	0.4	3
82	Secondary malignant neoplasms, progression-free survival and overall survival in patients treated for Hodgkin lymphoma: a systematic review and meta-analysis of randomized clinical trials. <i>Haematologica</i> , 2017, 102, 1748-1757.	3.5	38
83	A MALT lymphoma prognostic index. <i>Blood</i> , 2017, 130, 1409-1417.	1.4	149
84	¹⁸ F-FDG PET/CT in Lymphoma: Has Imaging-Directed Personalized Medicine Become a Reality?. <i>Journal of Nuclear Medicine</i> , 2017, 58, 1539-1544.	5.0	27
85	Antibody Tumor Targeting Is Enhanced by CD27 Agonists through Myeloid Recruitment. <i>Cancer Cell</i> , 2017, 32, 777-791.e6.	16.8	52
86	Positron Emission Tomography/Computed Tomography Assessment After Immunochemotherapy and Irradiation Using the Lugano Classification Criteria in the IELSG-26 Study of Primary Mediastinal B-Cell Lymphoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 97, 42-49.	0.8	31
87	The Dual Syk/JAK Inhibitor Cerdulatinib Antagonizes B-cell Receptor and Microenvironmental Signaling in Chronic Lymphocytic Leukemia. <i>Clinical Cancer Research</i> , 2017, 23, 2313-2324.	7.0	51
88	Final Results of the IELSG-19 Randomized Trial of Mucosa-Associated Lymphoid Tissue Lymphoma: Improved Event-Free and Progression-Free Survival With Rituximab Plus Chlorambucil Versus Either Chlorambucil or Rituximab Monotherapy. <i>Journal of Clinical Oncology</i> , 2017, 35, 1905-1912.	1.6	143
89	Short duration immunochemotherapy followed by radioimmunotherapy consolidation is effective and well tolerated in relapsed follicular lymphoma: 5-year results from a UK National Cancer Research Institute Lymphoma Group study. <i>British Journal of Haematology</i> , 2016, 173, 274-282.	2.5	12
90	Lymphoma: turning biology into cures. <i>Clinical Medicine</i> , 2016, 16, s125-s129.	1.9	5

#	ARTICLE	IF	CITATIONS
91	Response-adapted frontline therapy for Hodgkin lymphoma: are we there yet?. Hematology American Society of Hematology Education Program, 2016, 2016, 316-322.	2.5	17
92	Chemoimmunotherapy with methotrexate, cytarabine, thiopeta, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: results of the first randomisation of the International Extranodal Lymphoma Study Group-32 (IELSG32) phase 2 trial. Lancet Haematology,the, 2016, 3, e217-e227.	4.6	442
93	HD2000 Update in Hodgkin Lymphomaâ€”ABVD or BEACOPP?. Journal of Clinical Oncology, 2016, 34, 3584-3585.	1.6	1
94	PET-CT for staging and early response: results from the Response-Adapted Therapy in Advanced Hodgkin Lymphoma study. Blood, 2016, 127, 1531-1538.	1.4	143
95	Rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone (Râ€‹<scp>CHOP</scp>) in the management of primary mediastinal Bâ€‹cell lymphoma: a subgroup analysis of the <scp>UK NCRI</scp> Râ€‹<scp>CHOP</scp> 14 versus 21 trial. British Journal of Haematology, 2016, 175, 668-672.	2.5	38
96	IL-4 enhances expression and function of surface IgM in CLL cells. Blood, 2016, 127, 3015-3025.	1.4	76
97	The European Cancer Patientâ€™s Bill of Rights, update and implementation 2016. ESMO Open, 2016, 1, e000127.	4.5	36
98	The addition of rituximab to fludarabine and cyclophosphamide chemotherapy results in a significant improvement in overall survival in patients with newly diagnosed mantle cell lymphoma: results of a randomized UK National Cancer Research Institute trial. Haematologica, 2016, 101, 235-240.	3.5	24
99	Adapted Treatment Guided by Interim PET-CT Scan in Advanced Hodgkinâ€™s Lymphoma. New England Journal of Medicine, 2016, 374, 2419-2429.	27.0	629
100	Treatment of advanced-stage Hodgkin lymphoma. Seminars in Hematology, 2016, 53, 171-179.	3.4	22
101	The European Hematology Association Roadmap for European Hematology Research: a consensus document. Haematologica, 2016, 101, 115-208.	3.5	67
102	Recurrent mTORC1-activating RRAGC mutations in follicular lymphoma. Nature Genetics, 2016, 48, 183-188.	21.4	160
103	The Activated B-Cell Subtype of Diffuse Large B-Cell Lymphoma As Determined By Whole Genome Expression Profiling on Paraffin Embedded Tissue Is Independently Associated with Reduced Overall and Progression Free Survival in the Rituximab Era: Results from the UK NCRI R-CHOP 14 v 21 Phase III Trial. Blood. 2016. 128. 1746-1746.	1.4	9
104	A phase I, open-label study of GSK2816126, an enhancer of zeste homolog 2 (EZH2) inhibitor, in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL), transformed follicular lymphoma (tFL), other non-Hodgkinâ€™s lymphomas (NHL), multiple myeloma (MM) and solid tumor.. Journal of Clinical Oncology, 2016, 34, TPS2595-TPS2595.	1.6	11
105	Abstract B055: Augmentation of OX40-dependent NK mediated antitumor activity is dependent on antibody cross-linking. , 2016, , .		0
106	Abstract B046: Therapeutic mechanisms of anti-4-1BB antibodies in cancer: agonism versus regulatory T cell depletion. , 2016, , .		0
107	How I treat advanced classical Hodgkin lymphoma. Blood, 2015, 125, 1717-1723.	1.4	23
108	The PI3K/mTOR inhibitor PF-04691502 induces apoptosis and inhibits microenvironmental signaling in CLL and the EÂµ-TCL1 mouse model. Blood, 2015, 125, 4032-4041.	1.4	34

#	ARTICLE	IF	CITATIONS
109	Utility of baseline 18FDG-PET/CT functional parameters in defining prognosis of primary mediastinal (thymic) large B-cell lymphoma. <i>Blood</i> , 2015, 126, 950-956.	1.4	138
110	Long-term follow-up of MCL patients treated with single-agent ibrutinib: updated safety and efficacy results. <i>Blood</i> , 2015, 126, 739-745.	1.4	349
111	Which Metrics Are Appropriate to Describe the Value of New Cancer Therapies?. <i>BioMed Research International</i> , 2015, 2015, 1-9.	1.9	19
112	IV. Masses in the mediastinum: primary mediastinal lymphoma and intermediate types. <i>Hematological Oncology</i> , 2015, 33, 29-32.	1.7	20
113	Autologous Hematopoietic Stem Cell Transplantation for Refractory Crohn Disease. <i>JAMA - Journal of the American Medical Association</i> , 2015, 314, 2524.	7.4	136
114	Carmustine, Etoposide, Cytarabine, and Melphalan (BEAM)â€“Campath Allogeneic Stem Cell Transplantation for Aggressive Non-Hodgkin Lymphoma: An Analysis of Outcomes from the British Society of Blood and Marrow Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 483-488.	2.0	5
115	Conformation of the Human Immunoglobulin G2 Hinge Imparts Superagonistic Properties to Immunostimulatory Anticancer Antibodies. <i>Cancer Cell</i> , 2015, 27, 138-148.	16.8	135
116	The prognosis of <i>MYC</i> translocation positive diffuse large B-cell lymphoma depends on the second hit. <i>Journal of Pathology: Clinical Research</i> , 2015, 1, 125-133.	3.0	56
117	Principles of Chemotherapy in Hodgkin Lymphoma. <i>Hematologic Malignancies</i> , 2015, , 177-199.	0.2	0
118	Results of a Trial of PET-Directed Therapy for Early-Stage Hodgkinâ€™s Lymphoma. <i>New England Journal of Medicine</i> , 2015, 372, 1598-1607.	27.0	619
119	Antagonistic Human FcÎ³RIIB (CD32B) Antibodies Have Anti-Tumor Activity and Overcome Resistance to Antibody Therapy <i>In Vivo</i> . <i>Cancer Cell</i> , 2015, 27, 473-488.	16.8	108
120	Lessons for molecular diagnostics in oncology from the Cancer Research UK Stratified Medicine Programme. <i>Expert Review of Molecular Diagnostics</i> , 2015, 15, 287-289.	3.1	7
121	Clinical and Biological Effects of an Agonist Anti-CD40 Antibody: A Cancer Research UK Phase I Study. <i>Clinical Cancer Research</i> , 2015, 21, 1321-1328.	7.0	81
122	Expression of the inhibitory Fc gamma receptor <i>Î³</i> RIIB (FCGR2B, CD32B) on follicular lymphoma cells lowers the response rate to rituximab monotherapy (SAKK) Tj ETQq0 0 0 rgt /Overlock 10 Tf 5		
123	A collaborative approach to enabling stratified cancer medicine in the UK. <i>Drug Discovery Today</i> , 2015, 20, 1414-1418.	6.4	7
124	R-CHOP in Primary Mediastinal B-Cell Lymphoma (PMBL): Results from the UK NCRI R-CHOP 14 v 21 Trial. <i>Blood</i> , 2015, 126, 2689-2689.	1.4	3
125	A Prospective Randomised Trial of Targeted Therapy for Diffuse Large B-Cell Lymphoma (DLBCL) Based upon Real-Time Gene Expression Profiling: The Remodl-B Study of the UK NCRI and SAKK Lymphoma Groups (ISRCTN51837425). <i>Blood</i> , 2015, 126, 812-812.	1.4	20
126	Defining Immune Response Signatures in DLBCL As Potential Predictive Biomarkers for Outcome to Immunotherapy. <i>Blood</i> , 2015, 126, 2663-2663.	1.4	0

#	ARTICLE	IF	CITATIONS
127	Real-Time Molecular Classification of Diffuse Large B-Cell Lymphoma (DLBCL) By Gene Expression Profiling (GEP): Successful Delivery of a Routine Service for Randomization of Patients Onto the Multicenter Remodl-B Trial (ISRCTN 51837425). <i>Blood</i> , 2015, 126, 331-331.	1.4	0
128	Risk- and response-adapted strategies for the management of Hodgkin lymphoma. <i>Chinese Clinical Oncology</i> , 2015, 4, 13.	1.2	4
129	The Use of Anti-CD40 mAb in Cancer. <i>Current Topics in Microbiology and Immunology</i> , 2014, 405, 165-207.	1.1	21
130	Fc γ 3 Receptor Dependency of Agonistic CD40 Antibody in Lymphoma Therapy Can Be Overcome through Antibody Multimerization. <i>Journal of Immunology</i> , 2014, 193, 1828-1835.	0.8	56
131	Mogamulizumab and the treatment of CCR4-positive T-cell lymphomas. <i>Immunotherapy</i> , 2014, 6, 1187-1206.	2.0	33
132	[¹⁸ F]Fluorodeoxyglucose Positron Emission Tomography Predicts Survival After Chemoimmunotherapy for Primary Mediastinal Large B-Cell Lymphoma: Results of the International Extranodal Lymphoma Study Group IELSG-26 Study. <i>Journal of Clinical Oncology</i> , 2014, 32, 1769-1775.	1.6	149
133	Differential Impact of CD27 and 4-1BB Costimulation on Effector and Memory CD8 T Cell Generation following Peptide Immunization. <i>Journal of Immunology</i> , 2014, 193, 244-251.	0.8	46
134	Primary Mediastinal Large B-Cell Lymphoma. , 2014, , 195-206.		1
135	A national platform for molecular diagnostics: Results of the Cancer Research U.K. Stratified Medicine Programme.. <i>Journal of Clinical Oncology</i> , 2014, 32, 11079-11079.	1.6	1
136	A randomized, double-blind, placebo-controlled phase 3 study of ibrutinib in combination with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in subjects with newly diagnosed nongerminal center B-cell subtype of diffuse large B-cell lymphoma (DLBCL).. <i>Journal of Clinical Oncology</i> , 2014, 32, TPS8615-TPS8615.	1.6	9
137	Antibody Therapy in Oncology. , 2014, , 101-110.		0
138	Use of a biosimilar granulocyte colony-stimulating factor for peripheral blood stem cell mobilization: an analysis of mobilization and engraftment. <i>British Journal of Haematology</i> , 2013, 162, 107-111.	2.5	50
139	Fc γ 3R1 TM B controls the potency of agonistic anti-TNFR mAbs. <i>Cancer Immunology, Immunotherapy</i> , 2013, 62, 941-948.	4.2	41
140	Expression of inhibitory Fc receptor (Fc γ RIIB) is a marker of poor response to rituximab monotherapy in follicular lymphoma. <i>Lancet, The</i> , 2013, 381, S63.	13.7	3
141	Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma. <i>New England Journal of Medicine</i> , 2013, 369, 507-516.	27.0	1,449
142	Addition of Rituximab to Chlorambucil Produces Superior Event-Free Survival in the Treatment of Patients With Extranodal Marginal-Zone B-Cell Lymphoma: 5-Year Analysis of the IELSG-19 Randomized Study. <i>Journal of Clinical Oncology</i> , 2013, 31, 565-572.	1.6	198
143	Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a phase 3 comparison of dose intensification with 14-day versus 21-day cycles. <i>Lancet, The</i> , 2013, 381, 1817-1826.	13.7	450
144	Novel antibodies targeting immune regulatory checkpoints for cancer therapy. <i>British Journal of Clinical Pharmacology</i> , 2013, 76, 233-247.	2.4	38

#	ARTICLE	IF	CITATIONS
145	Antibody-peptide-MHC fusion conjugates target non-cognate T cells to kill tumour cells. <i>Cancer Immunology, Immunotherapy</i> , 2013, 62, 1093-1105.	4.2	10
146	A novel adaptive trial design: randomised evaluation of molecular guided therapy for diffuse large b-cell lymphoma with bortezomib (REMODL-B) with two interim analyses to explore safety and efficacy. <i>Trials</i> , 2013, 14, .	1.6	0
147	Management of early-stage Hodgkin lymphoma: is there still a role for radiation?. <i>Hematology American Society of Hematology Education Program</i> , 2013, 2013, 400-405.	2.5	9
148	III. Applying molecular phenotyping in practice. <i>Hematological Oncology</i> , 2013, 31, 29-32.	1.7	6
149	Safety and Clinical Activity of a Combination Therapy Comprising Two Antibody-Based Targeting Agents for the Treatment of Non-Hodgkin Lymphoma: Results of a Phase I/II Study Evaluating the Immunoconjugate Inotuzumab Ozogamicin With Rituximab. <i>Journal of Clinical Oncology</i> , 2013, 31, 573-583.	1.6	142
150	Is there a role for consolidation radiotherapy in Hodgkin's lymphoma in the era of the PET scan?. <i>International Journal of Hematologic Oncology</i> , 2013, 2, 27-38.	1.6	0
151	Utilizing a collaborative working model to optimize molecular analysis of solid tumors in the Cancer Research UK's Stratified Medicine Programme.. <i>Journal of Clinical Oncology</i> , 2013, 31, 11094-11094.	1.6	4
152	Patients With DLBCL Commonly Have B-Cell Lymphopenia and Circulating Clonal B-Cell Populations With a Phenotype Concordant With The Underlying Tumour. <i>Blood</i> , 2013, 122, 3013-3013.	1.4	2
153	A Universal Lectin-Mediated Interaction Drives B-Cell Receptor Signaling In Primary Follicular Lymphoma Cells. <i>Blood</i> , 2013, 122, 4291-4291.	1.4	0
154	A Phase I Clinical Trial of Irinotecan and Carboplatin in Patients with Extensive Stage Small Cell Lung Cancer. <i>Chemotherapy</i> , 2012, 58, 257-263.	1.6	5
155	Stratified medicine for cancer therapy. <i>Drug Discovery Today</i> , 2012, 17, 261-268.	6.4	5
156	Role of Positron Emission Tomography (PET/CT) in Primary Mediastinal Large B Cell Lymphoma (PMLBCL): Preliminary Results of an International Phase II Trial (IELSG-26 Study) Conducted On Behalf of the International Extranodal Lymphoma Study Group (IELSG), the Fondazione Italiana Linfomi (FIL) and the UK NCRI Lymphoma Group. <i>Blood</i> , 2012, 120, 1566-1566.	1.4	2
157	Emerging findings in the Cancer Research UK stratified medicine program.. <i>Journal of Clinical Oncology</i> , 2012, 30, TPS10633-TPS10633.	1.6	2
158	A Phase 1 Trial of Escalating High Dose Methotrexate Supported by Glucarpidase to Treat Patients with Primary Central Nervous System Lymphoma (PCNSL). (CRUK/08/010). <i>Blood</i> , 2012, 120, 4850-4850.	1.4	5
159	Expression of Inhibitory Fc Receptor (FcγRIIB) Is a Marker of Poor Response to Rituximab Monotherapy in Follicular Lymphoma (FL).. <i>Blood</i> , 2012, 120, 2747-2747.	1.4	0
160	Fc gamma receptor IIb on target B cells promotes rituximab internalization and reduces clinical efficacy. <i>Blood</i> , 2011, 118, 2530-2540.	1.4	226
161	S-adenosylhomocysteine hydrolase inhibition by 3-deazaneplanocin A analogues induces anti-cancer effects in breast cancer cell lines and synergy with both histone deacetylase and HER2 inhibition. <i>Breast Cancer Research and Treatment</i> , 2011, 127, 109-119.	2.5	94
162	Prediction of single nucleotide substitutions that result in exon skipping: identification of a splicing silencer in <i>BRCA1</i> exon 6. <i>Human Mutation</i> , 2011, 32, 436-444.	2.5	120

#	ARTICLE	IF	CITATIONS
163	Advanced Hodgkin lymphomaâ€”balancing toxicity and cure. <i>Nature Reviews Clinical Oncology</i> , 2011, 8, 634-636.	27.6	2
164	Establishment of a UK-wide network to facilitate the acquisition of quality assured FDGâ€”PET data for clinical trials in lymphoma. <i>Annals of Oncology</i> , 2011, 22, 739-745.	1.2	63
165	Principles of Chemotherapy in Hodgkin Lymphoma. , 2011, , 141-161.		1
166	Antigenic modulation limits the efficacy of anti-CD20 antibodies: implications for antibody selection. <i>Blood</i> , 2010, 115, 5191-5201.	1.4	292
167	Concordance between four European centres of PET reporting criteria designed for use in multicentre trials in Hodgkin lymphoma. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2010, 37, 1824-1833.	6.4	298
168	Enumeration and phenotypic assessment of human plasmacytoid and myeloid dendritic cells in whole blood. <i>Cytometry Part A: the Journal of the International Society for Analytical Cytology</i> , 2010, 77A, 328-337.	1.5	14
169	Weekly <i>versus</i> twice weekly bortezomib given in conjunction with rituximab, in patients with recurrent follicular lymphoma, mantle cell lymphoma and WaldenstrÅ“m macroglobulinaemia. <i>British Journal of Haematology</i> , 2010, 151, 346-353.	2.5	63
170	Initial dose intensity has limited impact on the outcome of ABVD chemotherapy for advanced Hodgkin lymphoma (HL): data from UKLG LY09 (ISRCTN97144519). <i>Annals of Oncology</i> , 2010, 21, 568-573.	1.2	12
171	Harnessing Innate Immunity to Suppress Lymphoma. <i>Journal of Clinical Oncology</i> , 2010, 28, 4295-4296.	1.6	4
172	Glycosylation of surface Ig creates a functional bridge between human follicular lymphoma and microenvironmental lectins. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2010, 107, 18587-18592.	7.1	151
173	Consolidation Radiotherapy in Patients With Advanced Hodgkin's Lymphoma: Survival Data From the UKLG LY09 Randomized Controlled Trial (ISRCTN97144519). <i>Journal of Clinical Oncology</i> , 2010, 28, 3352-3359.	1.6	79
174	The role of MNK proteins and eIF4E phosphorylation in breast cancer cell proliferation and survival. <i>Cancer Biology and Therapy</i> , 2010, 10, 728-735.	3.4	72
175	Anti-CD20 monoclonal antibodies: historical and future perspectives. <i>Haematologica</i> , 2010, 95, 135-143.	3.5	228
176	Cancer Research UK promotes research in surgery. <i>Bulletin of the Royal College of Surgeons of England</i> , 2009, 91, 194-195.	0.1	0
177	Randomized Comparison of the Stanford V Regimen and ABVD in the Treatment of Advanced Hodgkin's Lymphoma: United Kingdom National Cancer Research Institute Lymphoma Group Study ISRCTN 64141244. <i>Journal of Clinical Oncology</i> , 2009, 27, 5390-5396.	1.6	164
178	Thioflavin S (NSC71948) Interferes with Bcl-2-Associated Athanogene (BAG-1)-Mediated Protein-Protein Interactions. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2009, 331, 680-689.	2.5	30
179	Validation and comparison of two multiplex technologies, LuminexÅ“ and Mesoscale Discovery, for human cytokine profiling. <i>Journal of Immunological Methods</i> , 2009, 340, 55-64.	1.4	237
180	Short peptides derived from the BAGâ€”1 C-terminus inhibit the interaction between BAGâ€”1 and HSC70 and decrease breast cancer cell growth. <i>FEBS Letters</i> , 2009, 583, 3405-3411.	2.8	17

#	ARTICLE	IF	CITATIONS
181	Phase 1/2 study of fractionated 131I-rituximab in low-grade B-cell lymphoma: the effect of prior rituximab dosing and tumor burden on subsequent radioimmunotherapy. <i>Blood</i> , 2009, 113, 1412-1421.	1.4	79
182	Interim Analysis of the IELSG-19 Randomised Study of Chlorambucil Alone Versus Chlorambucil Plus Rituximab Versus Rituximab Alone in Extranodal Marginal Zone Lymphomas of Mucosa-Associated Lymphoid Tissue (MALT lymphoma).. <i>Blood</i> , 2009, 114, 3939-3939.	1.4	1
183	Anti-CD22 Immunoconjugate Inotuzumab Ozogamicin (CMC-544) + Rituximab: Clinical Activity Including Survival in Patients with Recurrent/Refractory Follicular or 'Aggressive' Lymphoma.. <i>Blood</i> , 2009, 114, 584-584.	1.4	19
184	Optimising anti-tumour CD8 T cell responses using combinations of immunomodulatory antibodies. <i>European Journal of Immunology</i> , 2008, 38, 2499-2511.	2.9	52
185	Primary mediastinal large B-cell lymphoma. <i>Critical Reviews in Oncology/Hematology</i> , 2008, 68, 256-263.	4.4	60
186	Will histone deacetylase inhibitors require combination with other agents to fulfil their therapeutic potential?. <i>British Journal of Cancer</i> , 2008, 99, 689-694.	6.4	82
187	Survival from non-Hodgkin lymphoma in England and Wales up to 2001. <i>British Journal of Cancer</i> , 2008, 99, S107-S109.	6.4	6
188	Intestinal strictures: a new complication of treatment for primary gastrointestinal diffuse large B-cell lymphoma. <i>British Journal of Haematology</i> , 2008, 140, 712-714.	2.5	7
189	Characterisation of the in vitro activity of the depsipeptide histone deacetylase inhibitor spiruchostatin A. <i>Biochemical Pharmacology</i> , 2008, 76, 463-475.	4.4	67
190	Primary Mediastinal B-Cell Lymphoma. <i>Hematology American Society of Hematology Education Program</i> , 2008, 2008, 349-358.	2.5	65
191	Induction of Cytosolic Calcium Flux by CD20 Is Dependent upon B Cell Antigen Receptor Signaling. <i>Journal of Biological Chemistry</i> , 2008, 283, 16971-16984.	3.4	118
192	First clinical use of ofatumumab, a novel fully human anti-CD20 monoclonal antibody in relapsed or refractory follicular lymphoma: results of a phase 1/2 trial. <i>Blood</i> , 2008, 111, 5486-5495.	1.4	247
193	BAG-1 inhibits PPAR γ -induced cell death, but not PPAR γ -induced transcription, cell cycle arrest or differentiation in breast cancer cells. <i>Oncology Reports</i> , 2008, , .	2.6	3
194	Results of the 2nd Planned Interim Analysis of the RAPID Trial (involved field radiotherapy versus no involved field radiotherapy) in patients with advanced-stage diffuse large B-cell lymphoma: FDG-PET Scan after 3 Cycles ABVD. <i>Blood</i> , 2008, 112, 369-369.	1.4	20
195	Randomised Comparison of the Stanford V (SV) Regimen and ABVD in the Treatment of Advanced Hodgkin Lymphoma (HL): Results from a UK NCRI Lymphoma Group Study, ISRCTN 64141244. <i>Blood</i> , 2008, 112, 370-370.	1.4	7
196	BAG-1 inhibits PPAR γ -induced cell death, but not PPAR γ -induced transcription, cell cycle arrest or differentiation in breast cancer cells. <i>Oncology Reports</i> , 2008, 19, 689-96.	2.6	11
197	Microscopic Intratumoral Dosimetry of Radiolabeled Antibodies Is a Critical Determinant of Successful Radioimmunotherapy in B-Cell Lymphoma. <i>Cancer Research</i> , 2007, 67, 1335-1343.	0.9	10
198	Eradication of lymphoma by CD8 T cells following anti-CD40 monoclonal antibody therapy is critically dependent on CD27 costimulation. <i>Blood</i> , 2007, 109, 4810-4815.	1.4	103

#	ARTICLE	IF	CITATIONS
199	Breast cancer is a promising target for vaccination using cancer-testis antigens known to elicit immune responses. <i>Breast Cancer Research</i> , 2007, 9, R46.	5.0	20
200	Pharmacological inhibitors of NF- κ B accelerate apoptosis in chronic lymphocytic leukaemia cells. <i>Oncogene</i> , 2007, 26, 1166-1177.	5.9	74
201	Late Events in Patients with Relapsed or Refractory Hodgkin's Lymphoma Treated with an Autologous Stem Cell Transplantation.. <i>Blood</i> , 2007, 110, 834-834.	1.4	0
202	Multi-Center Phase II Study of CAMPATH-1H Dose De-Escalation Prior to Nonmyeloablative HLA-Identical Sibling Transplantation.. <i>Blood</i> , 2007, 110, 1055-1055.	1.4	11
203	Therapeutic potential of immunostimulatory monoclonal antibodies. <i>Clinical Science</i> , 2006, 111, 93-106.	4.3	15
204	Immunohistochemical analysis of the antiapoptotic Mcl-1 and Bcl-2 proteins in follicular lymphoma. <i>British Journal of Haematology</i> , 2006, 132, 743-746.	2.5	18
205	The clinical outcome and toxicity of high-dose chemotherapy and autologous stem cell transplantation in patients with myeloma or amyloid and severe renal impairment: a British society of blood and marrow transplantation study. <i>British Journal of Haematology</i> , 2006, 134, 385-390.	2.5	55
206	Phase I study of Vinflunine administered as a 10-minute infusion on days 1 and 8 every 3 weeks. <i>Investigational New Drugs</i> , 2006, 24, 223-231.	2.6	42
207	Comparison of Outcomes in Studies of Advanced Hodgkin's Lymphoma. <i>Journal of Clinical Oncology</i> , 2006, 24, 3309-3309.	1.6	0
208	Bortezomib Therapy in Patients With Relapsed or Refractory Lymphoma: Potential Correlation of In Vitro Sensitivity and Tumor Necrosis Factor Alpha Response With Clinical Activity. <i>Journal of Clinical Oncology</i> , 2006, 24, 2105-2112.	1.6	163
209	Zanolimumab, a Fully Human Monoclonal Antibody: Preliminary Results of an Ongoing Clinical Trial in CD4+ Peripheral T-Cell Lymphomas (PTCL).. <i>Blood</i> , 2006, 108, 2723-2723.	1.4	1
210	A Phase II Study (BioV-121) of Clofarabine Monotherapy First Line in Patients Aged 65 Years or Older with Acute Myeloid Leukemia for Whom Standard Intensive Chemotherapy Is Not Considered Suitable.. <i>Blood</i> , 2006, 108, 425-425.	1.4	20
211	Gemcitabine Plus Carboplatin Versus Mitomycin, Ifosfamide, and Cisplatin in Patients With Stage IIIB or IV Non-Small-Cell Lung Cancer: A Phase III Randomized Study of the London Lung Cancer Group. <i>Journal of Clinical Oncology</i> , 2005, 23, 142-153.	1.6	152
212	Comparison of ABVD and Alternating or Hybrid Multidrug Regimens for the Treatment of Advanced Hodgkin's Lymphoma: Results of the United Kingdom Lymphoma Group LY09 Trial (ISRCTN97144519). <i>Journal of Clinical Oncology</i> , 2005, 23, 9208-9218.	1.6	130
213	Mcl-1. <i>International Journal of Biochemistry and Cell Biology</i> , 2005, 37, 267-271.	2.8	203
214	Targeted Radiotherapy in the Conditioning Prior to Haematopoietic Stem Cell Transplantation: Results of a Phase I Radiation Dose Escalation Study Using Yttrium-90-Labelled Anti-CD66 Monoclonal Antibody Demonstrating High BM Uptake of Radiation.. <i>Blood</i> , 2005, 106, 2189-2189.	1.4	12
215	Current Strategies to Target the Anti-Apoptotic Bcl-2 Protein in Cancer Cells. <i>Current Medicinal Chemistry</i> , 2004, 11, 1031-1040.	2.4	40
216	DNA vaccines to attack cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2004, 101, 14646-14652.	7.1	109

#	ARTICLE	IF	CITATIONS
217	Mcl-1 is required for Akata6 B-lymphoma cell survival and is converted to a cell death molecule by efficient caspase-mediated cleavage. <i>Oncogene</i> , 2004, 23, 4818-4827.	5.9	133
218	Antibody-induced intracellular signaling works in combination with radiation to eradicate lymphoma in radioimmunotherapy. <i>Blood</i> , 2004, 103, 1485-1494.	1.4	21
219	Prediction of Response to Recombinant Erythropoietin Plus Granulocyte-Colony Stimulating Factor Following a Single Subcutaneous Bolus in Patients with Myelodysplastic Syndromes; a Randomised Placebo Controlled Study.. <i>Blood</i> , 2004, 104, 1435-1435.	1.4	3
220	Stanford V (SV) Regimen Versus ABVD for the Treatment of Advanced Hodgkin Lymphoma (HL): Results of a UK NCRI/LTO Randomised Phase II Trial.. <i>Blood</i> , 2004, 104, 311-311.	1.4	1
221	Differential regulation of cell survival by CD40. <i>Apoptosis: an International Journal on Programmed Cell Death</i> , 2003, 8, 45-53.	4.9	48
222	Hdm2 Recruits a Hypoxia-Sensitive Corepressor to Negatively Regulate p53-Dependent Transcription. <i>Current Biology</i> , 2003, 13, 1234-1239.	3.9	65
223	The mechanisms of action of rituximab in the elimination of tumor cells. <i>Seminars in Oncology</i> , 2003, 30, 3-8.	2.2	186
224	The nuclear BAG-1 isoform, BAG-1L, enhances oestrogen-dependent transcription. <i>Oncogene</i> , 2003, 22, 4973-4982.	5.9	63
225	Primary Mediastinal B-Cell Lymphoma. <i>American Journal of Pathology</i> , 2003, 162, 243-253.	3.8	160
226	P-356 Addition of SRL172 (<i>Mycobacterium vaccae</i>) to standard chemotherapy in small cell lung cancer (SCLC) confers no survival benefit: Results of a randomised multicentre study. <i>Lung Cancer</i> , 2003, 41, S181-S182.	2.0	2
227	Complement-mediated lysis by anti-CD20 mAb correlates with segregation into lipid rafts. <i>Blood</i> , 2003, 101, 1045-1052.	1.4	353
228	Anti-CD40 monoclonal antibody therapy in combination with irradiation results in a CD8 T-cell-dependent immunity to B-cell lymphoma. <i>Blood</i> , 2003, 102, 1449-1457.	1.4	81
229	Hdm2 Recruits the Hypoxia Sensitive Transcriptional Co-Repressor CtBP2 to Negatively Regulate p53-Dependant Transcription. <i>Clinical Science</i> , 2003, 104, 29P-29P.	0.0	0
230	CD40 Induces Interleukin-6 Gene Transcription in Dendritic Cells. <i>Journal of Biological Chemistry</i> , 2002, 277, 17125-17138.	3.4	86
231	The Effects of Malignant Transformation on Susceptibility of Human Urothelial Cells to CD40-Mediated Apoptosis. <i>Journal of the National Cancer Institute</i> , 2002, 94, 1381-1395.	6.3	52
232	Mechanism of action of rituximab. <i>Anti-Cancer Drugs</i> , 2002, 13, S3-S10.	1.4	161
233	Acquisition of potential N-glycosylation sites in the immunoglobulin variable region by somatic mutation is a distinctive feature of follicular lymphoma. <i>Blood</i> , 2002, 99, 2562-2568.	1.4	237
234	Molecular remission and non-Hodgkin's lymphoma. <i>Best Practice and Research in Clinical Haematology</i> , 2002, 15, 549-562.	1.7	7

#	ARTICLE	IF	CITATIONS
235	Bone marrow transplants. <i>BMJ: British Medical Journal</i> , 2002, 325, 348-349.	2.3	1
236	Spontaneous clinical regression in chronic lymphocytic leukaemia. <i>British Journal of Haematology</i> , 2002, 116, 341-345.	2.5	34
237	The therapeutic use of antibodies for malignancy. <i>Transfusion Clinique Et Biologique</i> , 2001, 8, 255-259.	0.4	5
238	Rituximab: mechanisms and applications. <i>British Journal of Cancer</i> , 2001, 85, 1619-1623.	6.4	86
239	A UK multicentre phase II study of rituximab (chimaeric anti-CD20 monoclonal antibody) in patients with follicular lymphoma, with PCR monitoring of molecular response. <i>British Journal of Haematology</i> , 2000, 109, 81-88.	2.5	101
240	Clinical trials of antibody therapy. <i>Trends in Immunology</i> , 2000, 21, 403-410.	7.5	277
241	Identification of a novel human BCL-X promoter and exon. <i>Oncogene</i> , 2000, 19, 5534-5538.	5.9	15
242	Persistence of clonal T-cell expansions following high-dose chemotherapy and autologous peripheral blood progenitor cell rescue. <i>British Journal of Haematology</i> , 2000, 111, 766-773.	2.5	2
243	High-Dose Therapy With Autologous Bone Marrow Support as Consolidation of Remission in Follicular Lymphoma: Long-Term Clinical and Molecular Follow-Up. <i>Journal of Clinical Oncology</i> , 2000, 18, 527-527.	1.6	168
244	European Phase II Study of Rituximab (Chimeric Anti-CD20 Monoclonal Antibody) for Patients With Newly Diagnosed Mantle-Cell Lymphoma and Previously Treated Mantle-Cell Lymphoma, Immunocytoma, and Small B-Cell Lymphocytic Lymphoma. <i>Journal of Clinical Oncology</i> , 2000, 18, 317-317.	1.6	448
245	Persistence of clonal T-cell expansions following high-dose chemotherapy and autologous peripheral blood progenitor cell rescue. <i>British Journal of Haematology</i> , 2000, 111, 766-773.	2.5	5
246	Marimastat in recurrent colorectal cancer: exploratory evaluation of biological activity by measurement of carcinoembryonic antigen. <i>British Journal of Cancer</i> , 1999, 79, 509-514.	6.4	71
247	A stimulating new target for cancer immunotherapy. <i>Lancet, The</i> , 1999, 354, 1225-1227.	13.7	17
248	Variability of polymerase chain reaction detection of the bcl-2-IgH translocation in an international multicentre study. <i>Annals of Oncology</i> , 1999, 10, 1349-1354.	1.2	38
249	EFFECTS OF INTERLEUKIN 6 ADMINISTRATION ON PLATELETS AND HAEMOPOIETIC PROGENITOR CELLS IN PERIPHERAL BLOOD. <i>Cytokine</i> , 1996, 8, 717-723.	3.2	27
250	Serum neuron-specific enolase (S-NSE) and the prognosis in small-cell lung cancer (SCLC): a combined multivariable analysis on data from nine centres. <i>British Journal of Cancer</i> , 1996, 74, 463-467.	6.4	82
251	Allele Imbalance at Tumour Suppressor Loci During the Indolent Phase of Follicle Centre Cell Lymphoma. <i>Leukemia and Lymphoma</i> , 1996, 22, 113-117.	1.3	1
252	Patterns of survival in patients with recurrent follicular lymphoma: a 20-year study from a single center.. <i>Journal of Clinical Oncology</i> , 1995, 13, 140-147.	1.6	319

#	ARTICLE	IF	CITATIONS
253	The molecular detection of circulating tumour cells. British Journal of Cancer, 1995, 72, 268-276.	6.4	149
254	Detection of cells bearing the t(14;18) translocation following myeloablative treatment and autologous bone marrow transplantation for follicular lymphoma.. Journal of Clinical Oncology, 1994, 12, 798-805.	1.6	92
255	Myeloablative therapy with autologous bone marrow transplantation as consolidation therapy for recurrent follicular lymphoma.. Journal of Clinical Oncology, 1994, 12, 1177-1184.	1.6	218
256	A randomized trial of two etoposide schedules in small-cell lung cancer: the influence of pharmacokinetics on efficacy and toxicity.. Journal of Clinical Oncology, 1994, 12, 1427-1435.	1.6	108